Plozasiran预防极重度高甘油三酯血症成人复发性胰腺炎:PALISADE 3期试验事后分析
PALISADE为国际多中心双盲安慰剂对照试验,极重度高甘油三酯血症患者按2:1:2:1随机接受皮下Plozasiran(25或50mg)或安慰剂每季度一次共12个月;事后分析纳入67例有至少一次急性胰腺炎(AP)史者,Plozasiran组复发性AP风险降低83%(HR 0.17,95%CI 0.03-0.87,p<0.017)。
要点
- Plozasiran使中位TG降幅>75%,中位水平降至<5.65 mmol/L(500 mg/dL)。
- 复发性AP事件安慰剂组5/22例,Plozasiran组2/45例,风险降低83%。
- Plozasiran组AP严重程度、腹痛住院率及住院时长均更低。
核心结论
- Plozasiran显著降低循环TG水平,并大幅减少极重度高甘油三酯血症且有AP史患者的复发性AP。
- Plozasiran是首个在家族性乳糜微粒血症综合征(FCS)患者前瞻性随机试验中显示复发性AP统计学显著降低的疗法。
研究设计与样本
- PALISADE为国际、多中心、双盲、安慰剂对照试验,患者按2:1:2:1随机接受皮下Plozasiran(25或50mg)或容积匹配安慰剂,每季度一次共12个月。
- 本分析为事后分析,纳入有至少一次既往AP发作史的参与者,共67例,基线中位TG>22.6 mmol/L(2000 mg/dL)。
主要发现
- Plozasiran治疗者中位TG降幅>75%,中位水平降至<5.65 mmol/L(500 mg/dL)。
- 复发性AP发生于安慰剂组22例中5例,汇总Plozasiran组45例中2例,风险降低83%(HR 0.17;95%CI [0.03, 0.87],p<0.017)。
- Plozasiran组AP严重程度、腹痛住院率及住院时长均更低。
关键数值与推荐
- 主要及α控制次要终点包括专家裁定的AP发生率和胰腺炎相关住院。
- 复发性AP风险降低83%(HR 0.17;95%CI [0.03, 0.87],p<0.017)。
临床怎么用
- 对极重度高甘油三酯血症且有AP史的患者,Plozasiran可显著降低TG并减少复发性AP风险。
- Plozasiran组AP严重程度及胰腺炎相关住院负担更低,支持其用于复发性AP预防。
局限性
- 本分析为PALISADE试验的事后分析,样本量较小(67例)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with persistent chylomicronaemia (PC) are at high risk for acute pancreatitis (AP). Plozasiran, a small interfering RNA, reduces hepatic apolipoprotein C-III, significantly lowers triglyceride (TG) levels and reduces risk of AP. AIM: To assess the effect of plozasiran on recurrent AP in patients with severe hypertriglyceridemia and history of pancreatitis. METHODS: PALISADE was an international, multicentre, double-blind, placebo-controlled trial. Patients with extreme hypertriglyceridemia were randomised 2:1:2:1 to receive subcutaneous plozasiran (25- or 50-mg) or volume-matched placebo, quarterly for 12 months. This post hoc analysis involved participants with a history of at least one prior episode of AP. Primary and alpha-controlled secondary endpoints included the incidence of expert-adjudicated AP and pancreatitis-related hospitalisations. RESULTS: The analysis included 67 participants with median baseline TG > 22.6 mmol/L (2000 mg/dL). Plozasiran-treated participants experienced a > 75% reduction in median TG, with median levels falling below 5.65 mmol/L (500 mg/dL). Incident AP occurred in 5 of 22 in the placebo group versus 2 of 45 in the pooled plozasiran group, representing an 83% (HR, 0.17; 95% CI [0.03, 0.87], p < 0.017) reduction in risk for recurrent AP in the plozasiran group. AP severity, hospitalisation rates for abdominal pain, and length of hospital stay were lower in the plozasiran group. CONCLUSIONS: Plozasiran significantly lowered circulating TG levels, with substantial reduction in recurrent AP for participants with very severe hypertriglyceridemia and history of AP. Plozasiran is the first therapy to demonstrate a statistically significant reduction in recurrent AP in a prospective randomised trial of patients with familial chylomicronaemia syndrome (FCS). TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT05089084.
引用
- Loomba R, de-Madaria E, Afghani E, et al. Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study. Aliment Pharmacol Ther. 2026. PMID: 41923352. doi:10.1111/apt.70623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。